-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels: What are the advantages of CDX modeling platform?
Author:
InnoModels
Release time:
2024-05-28
In the field of biomedicine, cancer research has always been an important topic that scientists are constantly striving to overcome. With the continuous advancement of technology, more and more innovative methods have been applied to this field, among which the CDX modeling platform of InnoModels Biotechnology provides strong support for cancer research and drug development with its unique advantages.
The CDX model platform of InnoModels is based on the xenografting technology of cancer tissues, in which cancer tissues from patients are transplanted into animals to form human-derived xenograft tumors, so as to construct cancer models that highly simulate human diseases. This technology not only preserves the heterogeneity and complexity of the original tumor tissue, but also enables researchers to gain a more comprehensive understanding of the complex characteristics of tumors, providing a more accurate data base for precision medicine research.
The core advantage of the platform is its ability to highly preserve the heterogeneity of the original cancer tissue. This means that the diversity of tumor cells, tissue structure, and the interaction between the tumor and surrounding tissues are well preserved in the CDX model. This enables researchers to more realistically simulate the growth and metastasis of tumors in the human body, and then study the development mechanism of tumors in depth, providing a scientific basis for the development of precise treatment plans.

In addition, the high portability of the CDX model in animals is also one of its important advantages. This high portability makes the CDX model an ideal platform for drug development. Researchers can assess the therapeutic effects of different drugs on tumors and predict the response of drugs in the human body through the CDX model, thus accelerating the R&D process of new drugs.
It is worth mentioning that InnoModels Biotechnology also has a large library of tumor cell lines covering a wide range of cancer types and subtypes. This provides researchers with an abundance of choices, enabling them to select the most suitable cell lines according to their research needs, further improving the accuracy and reliability of their studies.
In addition to its technological advantages, InnoModels Biotechnology also has an experienced team of professionals. The team members have a deep theoretical foundation and practical experience in the field of CDX modeling, and are able to provide researchers with a full range of technical support and solutions. At the same time, InnoModels Biotechnology also focuses on the traceability of experiments and the reliability of data to ensure that every research result has been strictly verified and audited.
In the field of cancer research, the application of CDX model has achieved remarkable results. Through the CDX model, researchers have not only gained an in-depth understanding of the tumor development mechanism, but also successfully screened out a series of potential drug candidates. These results have provided strong support for the precision treatment of cancer and brought more hope to patients.
In conclusion, with its unique advantages and powerful functions, InnoModels' CDX modeling platform has injected new vitality into cancer research and drug development. With the continuous development and improvement of the technology, it is believed that CDX model will play an even more important role in the future biomedical field and make greater contributions to human health.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd